News
-
GSK has announced that the European Commission has granted marketing authorization for its Incruse Ellipta umeclidinium DPI for the treatment of COPD with a dosage of 55 mcg. According to the company’s announcement, launches in… Read more . . .
-
The European Commission has approved Teva’s DuoResp Spiromax budesonide/formoterol DPI for the treatment of asthma and COPD, the company has announced. The EMA’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion… Read more . . .
-
NanoBio Corporation has announced that it will present promising pre-clinical study data of its nano-emulsion (NE)-adjuvanted intranasal herpes simplex virus-2 (HSV-2) vaccine at the Annual Conference on Vaccine Research. NanoBio Senior VP of Vaccine Research… Read more . . .
-
Civitas Therapeutics has announced positive results from a Phase 2b trial of its CVT-301 inhaled L-dopa for the treatment of Parkinson’s disease symptoms. The company is developing CVT-301 based on its proprietary ARCUS particle engineering… Read more . . .
-
GSK and Theravance have announced the launch of Anoro Ellipta umeclidinium/vilanterol inhalation powder in the United States, triggering a $30 million milestone payment from Theravance to GSK. The FDA approved Anoro Ellipta for the treatment… Read more . . .
-
Submit poster and paper abstracts by July 25, 2014 online at http://www.ddl-conference.org.uk/?q=abstractsubmissionDDL25. Visit http://www.ddl-conference.org.uk/index.php?q=abstractsubmission to view the session themes and download abstract guidelines. Read more . . .
-
The US FDA has proposed a new rule that would require e-cigarette makers to register with the agency, disclose ingredients used in their inhalation solutions, and provide scientific evidence to support claims of reduced risk… Read more . . .
-
Australia’s Therapeutic Goods Administration (TGA) has approved the Breo Ellipta fluticasone furoate/vilanterol for the treatment of asthma and COPD, according to GSK Australia and Theravance. GSK Medical Director Andrew Yeates commented, “We are delighted that… Read more . . .
-
The FDA has granted orphan drug designation to a ciprofloxacin DPI being developed by Bayer HealthCare for the treatment of non-cystic fibrosis bronchiectasis, the company has announced. The dry powder formulation, based on Novartis’s PulmoSphere… Read more . . .
-
Theravance has announced that its LABA Royalty Sub wholly owned subsidiary “issued $450 million in aggregate principal amount of PhaRMA 9% Notes due on or before May 15, 2029. The notes are secured by a… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.